BRCA2 and breast neoplasm: When we assessed the generality of the relationship between HUWE1 loss of function and PARPi resistance in additional cell lines, we noted that BRCA1/2 wild type CAL51 breast tumour cells (Fig. 2E) or BRCA2 mutant Capan1 pancreatic tumour cells (Fig. 2F) did not display PARPi resistance upon HUWE1 silencing; in fact, CAL51 cells showed a slight increase in PARPi sensitivity upon HUWE1 silencing (Fig. 2E), suggesting that the effect of HUWE1 on PARPi sensitivity/resistance might be contextualised by the status of BRCA1.